{"groups":[{"description":"Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles","id":"FG000","title":"Ripretinib"},{"description":"Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.","id":"FG001","title":"Sunitinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"24"}],"type":"Participants ongoing."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"226"},{"groupId":"FG001","numSubjects":"227"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"190"},{"groupId":"FG001","numSubjects":"203"}],"comment":"Completed patients are defined as patients that are followed until death or until the sponsor terminates the study.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}